Five Stocks Added to Zacks Rank #1 List for October 3rd
ByAinvest
Friday, Oct 3, 2025 4:19 am ET1min read
AEG--
Dorman Products, an auto parts manufacturer, has seen its stock price rise due to positive analyst ratings. Stephens and Roth Capital have both initiated coverage with "overweight" ratings and price targets of $185.00 and $182.00 respectively, indicating a potential upside of 22.09% and 17.25% from their previous close [1].
Aegon, a global life insurance company, was upgraded from a "hold" to a "strong-buy" rating by Zacks Research and Wall Street Zen [2]. This upgrade comes as institutional investors and analysts express confidence in the company's growth prospects.
Genmab, a biotechnology company, has also seen an increase in its earnings estimates, reflecting positive sentiment among analysts. Similarly, ScanSource, a technology solutions provider, and Gold Fields Limited, a mining company, have seen their earnings estimates rise, indicating a potential for increased profitability.
These upgrades highlight the growing optimism among financial professionals and investors about the future prospects of these companies. As always, investors should conduct thorough research and consider their risk tolerance before making any investment decisions.
DORM--
GFI--
GMAB--
SCSC--
Dorman Products, Aegon, Genmab, ScanSource, and Gold Fields Limited have been added to the Zacks Rank #1 (Strong Buy) List today. Their current year earnings estimates have increased 11.5%, 10.1%, 10.1%, 7.9%, and 7% respectively over the last 60 days.
Today, Dorman Products (NASDAQ: DORM), Aegon (NYSE: AEG), Genmab (CSE: GENM), ScanSource (NASDAQ: SC), and Gold Fields Limited (NYSE: GFI) were added to the Zacks Rank #1 (Strong Buy) List. This move is based on significant upward revisions in their current year earnings estimates over the last 60 days. The earnings estimates for these companies have increased by 11.5%, 10.1%, 10.1%, 7.9%, and 7% respectively.Dorman Products, an auto parts manufacturer, has seen its stock price rise due to positive analyst ratings. Stephens and Roth Capital have both initiated coverage with "overweight" ratings and price targets of $185.00 and $182.00 respectively, indicating a potential upside of 22.09% and 17.25% from their previous close [1].
Aegon, a global life insurance company, was upgraded from a "hold" to a "strong-buy" rating by Zacks Research and Wall Street Zen [2]. This upgrade comes as institutional investors and analysts express confidence in the company's growth prospects.
Genmab, a biotechnology company, has also seen an increase in its earnings estimates, reflecting positive sentiment among analysts. Similarly, ScanSource, a technology solutions provider, and Gold Fields Limited, a mining company, have seen their earnings estimates rise, indicating a potential for increased profitability.
These upgrades highlight the growing optimism among financial professionals and investors about the future prospects of these companies. As always, investors should conduct thorough research and consider their risk tolerance before making any investment decisions.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet